Li Gao1, Erfu Xie1, Tongfu Yu1, Dan Chen1, Lixia Zhang1, Bingfeng Zhang1, Fang Wang1, Jian Xu1, Peijun Huang1, Xisheng Liu1, Bingliang Fang1, Shiyang Pan1. 1. 1 Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 National Key Clinical, Department of Laboratory Medicine, Nanjing 210029, China ; 3 Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 4 Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract
BACKGROUND: Inactivation of tumor-suppressor gene (TSG) by promoter hypermethylation has been reported in many tumor types, including lung cancer. This study was designed to determine the methylated APC and RASSF1A genes in tumor tissue, serum and plasma of patients with early stage lung cancer. METHODS: Eighty-nine patients with undetermined solitary pulmonary nodules detected upon CT-scan were recruited in this study. DNA samples were extracted from biopsy tissues, serum and plasma and QMSP of APC and RASSF1A was carried out after bisulfite conversion. The 89 patients consist of 58 stage I lung cancer patients and 31 benign lung disease according to pathological report. Twenty-six cancer patients had matched biopsy tumor tissue, serum and plasma samples. RESULTS: The methylation rates of APC and RASSF1A were 59.0% and 66.1% in biopsy tissues, 42.5% and 52.5% in serum, and 24.1% and 43.1% in plasma of cancer patients. For RASSF1A, different samples all showed a significant difference between cancer group and benign group (P<0.05). However, APC gene only explored the P value less than 0.05 in plasma result. Towards the 26 lung cancer patients with three matched samples, methylation rate in each sample type was more than 50.0% and displayed no difference. CONCLUSIONS: Evaluation of APC and RASSF1A promoter methylation by using QMSP appears to be very useful for the differential diagnosis of patients with undetermined solitary pulmonary nodules. Our results also suggested that plasma might be the best sample for clinical detection of early stage lung.
BACKGROUND: Inactivation of tumor-suppressor gene (TSG) by promoter hypermethylation has been reported in many tumor types, including lung cancer. This study was designed to determine the methylated APC and RASSF1A genes in tumor tissue, serum and plasma of patients with early stage lung cancer. METHODS: Eighty-nine patients with undetermined solitary pulmonary nodules detected upon CT-scan were recruited in this study. DNA samples were extracted from biopsy tissues, serum and plasma and QMSP of APC and RASSF1A was carried out after bisulfite conversion. The 89 patients consist of 58 stage I lung cancerpatients and 31 benign lung disease according to pathological report. Twenty-six cancerpatients had matched biopsy tumor tissue, serum and plasma samples. RESULTS: The methylation rates of APC and RASSF1A were 59.0% and 66.1% in biopsy tissues, 42.5% and 52.5% in serum, and 24.1% and 43.1% in plasma of cancerpatients. For RASSF1A, different samples all showed a significant difference between cancer group and benign group (P<0.05). However, APC gene only explored the P value less than 0.05 in plasma result. Towards the 26 lung cancerpatients with three matched samples, methylation rate in each sample type was more than 50.0% and displayed no difference. CONCLUSIONS: Evaluation of APC and RASSF1A promoter methylation by using QMSP appears to be very useful for the differential diagnosis of patients with undetermined solitary pulmonary nodules. Our results also suggested that plasma might be the best sample for clinical detection of early stage lung.
Authors: Victoria K Hill; Luke B Hesson; Temuujin Dansranjavin; Ashraf Dallol; Ivan Bieche; Sophie Vacher; Stella Tommasi; Timothy Dobbins; Dean Gentle; David Euhus; Cheryl Lewis; Reinhard Dammann; Robyn L Ward; John Minna; Eammon R Maher; Gerd P Pfeifer; Farida Latif Journal: Mol Cancer Date: 2010-03-05 Impact factor: 27.401
Authors: H E Mulcahy; J Lyautey; C Lederrey; X qi Chen; P Anker; E M Alstead; A Ballinger; M J Farthing; M Stroun Journal: Clin Cancer Res Date: 1998-02 Impact factor: 12.531
Authors: Malcolm V Brock; Craig M Hooker; Emi Ota-Machida; Yu Han; Mingzhou Guo; Stephen Ames; Sabine Glöckner; Steven Piantadosi; Edward Gabrielson; Genevieve Pridham; Kristen Pelosky; Steven A Belinsky; Stephen C Yang; Stephen B Baylin; James G Herman Journal: N Engl J Med Date: 2008-03-13 Impact factor: 91.245
Authors: Guro E Lind; Stine A Danielsen; Terje Ahlquist; Marianne A Merok; Kim Andresen; Rolf I Skotheim; Merete Hektoen; Torleiv O Rognum; Gunn I Meling; Geir Hoff; Michael Bretthauer; Espen Thiis-Evensen; Arild Nesbakken; Ragnhild A Lothe Journal: Mol Cancer Date: 2011-07-21 Impact factor: 27.401
Authors: Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Georgia Pitsiou; Bernd Linsmeier; Drosos Tsavlis; Ioannis Kioumis; Eleni Papadaki; Lutz Freitag; Theodora Tsiouda; J Francis Turner; Robert Browning; Michael Simoff; Nikolaos Sachpekidis; Kosmas Tsakiridis; Bojan Zaric; Lonny Yarmus; Sofia Baka; Grigoris Stratakos; Harald Rittger Journal: J Cancer Date: 2016-01-13 Impact factor: 4.207
Authors: Eloy Povedano; Eva Vargas; Víctor Ruiz-Valdepeñas Montiel; Rebeca M Torrente-Rodríguez; María Pedrero; Rodrigo Barderas; Pablo San Segundo-Acosta; Alberto Peláez-García; Marta Mendiola; David Hardisson; Susana Campuzano; José M Pingarrón Journal: Sci Rep Date: 2018-04-23 Impact factor: 4.379